- November 13, 2015
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Masayuki Kobayashi) announced that it has submitted an application on November 13 for approval of the manufacture and marketing of TAC-202 (generic name: bilastine), an oral anti-allergy drug, to the Japanese Ministry of Health, Labour and Welfare. Taiho is seeking approval of TAC-202 for the indication of allergic rhinitis, urticaria, and itching resulting from skin diseases (eczema/dermatitis, prurigo, and cutaneous pruritus).
TAC-202, is an innovative anti-histamine product, discovered by Faes Farma S.A. in Spain (HQ: Leioa, President: Mariano Ucar Angulo,"Faes Farma") and was first approved in European Union in 2010. Taiho has developed TAC-202 after signing a license agreement with Faes Farma in July 2012 for the development and marketing rights in Japan. The product has been successfully approved in over 90 countries and regions* and marketed by several partners under the license from Faes Farma for the treatment of allergic rhinitis and urticaria.
* As of May 2015(latest)
Taiho will dedicate its effort to further contribute to patients and medical care providers for the treatment of allergic disorders.
About Faes Farma S.A.
Faes Farma S.A. is one of the leading Spanish pharmaceutical companies, focused on research, manufacture and commercialization of innovative medicines.
With strong presence also in Portugal, Latin America and Africa, Faes Farma is now developing an intense process of internationalization. Bilastine shall be a key element in this process. For more information about Faes Farma, please visit the company's website at http://www.faes.es/.
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.